{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:06:00Z","timestamp":1786975560446,"version":"build-2736575974"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine whether the effects of RAS blockers on cardiovascular outcomes differ between Black patients and non-Black patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>MEDLINE and Embase databases through December 31, 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Randomized trials investigating the effect of RAS blockers on cardiovascular outcomes in adults with HFrEF that enrolled Black and non-Black patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>\n                      Individual-participant data were extracted following Preferred Reporting Items for Systematic Reviews and Meta-analyses Independent Personal Data (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.equator-network.org\/reporting-guidelines\/prisma\/\">PRISMA<\/jats:ext-link>\n                      -IPD) reporting guidelines. Effects were estimated using a mixed-effects model using a 1-stage approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome and Measure<\/jats:title>\n                    <jats:p>The primary outcome was first hospitalization for HF or cardiovascular death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary analysis, based on the 3 placebo-controlled RAS inhibitor monotherapy trials, included 8825 patients (9.9% Black). Rates of death and hospitalization for HF were substantially higher in Black than non-Black patients. The hazard ratio (HR) for RAS blockade vs placebo for the primary composite was 0.84 (95% CI, 0.69-1.03) in Black patients and 0.73 (95% CI, 0.67-0.79) in non-Black patients (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.14). The HR for first HF hospitalization was 0.89 (95% CI, 0.70-1.13) in Black patients and 0.62 (95% CI, 0.56-0.69) in non-Black patients (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.006). Conversely, the corresponding HRs for cardiovascular death were 0.83 (95% CI, 0.65-1.07) and 0.84 (95% CI, 0.77-0.93), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.99). For total hospitalizations for HF and cardiovascular deaths, the corresponding rate ratios were 0.82 (95% CI, 0.66-1.02) and 0.72 (95% CI, 0.66-0.80), respectively (\n                      <jats:italic>P<\/jats:italic>\n                      for interaction\u2009=\u2009.27). The supportive analyses including the 2 trials adding an angiotensin receptor blocker to background angiotensin-converting enzyme inhibitor treatment (n\u2009=\u200916\u202f383) gave consistent findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The mortality benefit from RAS blockade was similar in Black and non-Black patients. Despite the smaller relative risk reduction in hospitalization for HF with RAS blockade in Black patients, the absolute benefit in Black patients was comparable with non-Black patients because of the greater incidence of this outcome in Black patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.6774","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:00:54Z","timestamp":1716980454000},"page":"2094","source":"Crossref","is-referenced-by-count":12,"title":["Revisiting Race and the Benefit of RAS Blockade in Heart Failure"],"prefix":"10.1001","volume":"331","author":[{"given":"Li","family":"Shen","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Hangzhou Normal University, Hangzhou, China"},{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M. Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Division of Cardiology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder S.","family":"Anand","sequence":"additional","affiliation":[{"name":"Veterans Affairs Medical Center and University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"ANMCO Research Center, Heart Care Foundation, Florence, Italy"},{"name":"Division of Cardiology, Garibaldi-Nesima Hospital, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Swedberg","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[{"name":"Population Health Research Institute and Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"joi240055r1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1071-9164(99)90001-5","article-title":"Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials.","volume":"5","author":"Carson","year":"1999","journal-title":"J Card Fail"},{"issue":"18","key":"joi240055r2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.","volume":"344","author":"Exner","year":"2001","journal-title":"N Engl J Med"},{"issue":"13","key":"joi240055r3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"joi240055r4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7326\/0003-4819-141-8-200410190-00009","article-title":"Systematic review: antihypertensive drug therapy in black patients.","volume":"141","author":"Brewster","year":"2004","journal-title":"Ann Intern Med"},{"issue":"11","key":"joi240055r5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1161\/CIRCULATIONAHA.123.065887","article-title":"Are recommendations that favor other agents over angiotensin-converting enzyme inhibitors in Africans with hypertension justified?","volume":"149","author":"Peter","year":"2024","journal-title":"Circulation"},{"issue":"5","key":"joi240055r6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"joi240055r7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"joi240055r8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"1","key":"joi240055r9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/chf.2004.10.issue-1","article-title":"Racial response to angiotensin-converting enzyme therapy in systolic heart failure.","volume":"10","author":"Dries","year":"2004","journal-title":"Congest Heart Fail"},{"issue":"5","key":"joi240055r10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2165\/00129784-200707050-00007","article-title":"Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate\/hydralazine in the African-American Heart Failure Trial.","volume":"7","author":"Ghali","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"issue":"8","key":"joi240055r11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.cardfail.2015.05.013","article-title":"Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee.","volume":"21","author":"Colvin","year":"2015","journal-title":"J Card Fail"},{"issue":"10","key":"joi240055r12","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jchf.2020.06.019","article-title":"Angiotensin-neprilysin inhibition in black Americans: data from the PIONEER-HF Trial.","volume":"8","author":"Berardi","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"16","key":"joi240055r13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"9386","key":"joi240055r14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9386","key":"joi240055r15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"joi240055r16","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"joi240055r17","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"17","key":"joi240055r18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"joi240055r20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events.","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc B"},{"issue":"11","key":"joi240055r21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.v21:11","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7109","key":"joi240055r22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"19","key":"joi240055r23","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race.","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"joi240055r24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines, 1: introduction-GRADE evidence profiles and summary of findings tables.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"17","key":"joi240055r25","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"issue":"1","key":"joi240055r26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"joi240055r27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ahj.2017.10.025","article-title":"Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction.","volume":"197","author":"Sullivan","year":"2018","journal-title":"Am Heart J"},{"issue":"3","key":"joi240055r28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ahj.2007.10.022","article-title":"Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).","volume":"155","author":"Mitchell","year":"2008","journal-title":"Am Heart J"},{"issue":"8","key":"joi240055r29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007264","article-title":"Understanding the complexity of heart failure risk and treatment in Black patients.","volume":"13","author":"Nayak","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"2","key":"joi240055r30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0735-1097(02)01943-5","article-title":"Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in Black and White patients.","volume":"40","author":"Dries","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"43","key":"joi240055r31","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1093\/eurheartj\/ehab360","article-title":"Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.","volume":"42","author":"Lam","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"joi240055r32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jchf.2021.08.006","article-title":"Efficacy of dapagliflozin in Black versus White patients with heart failure and reduced ejection fraction.","volume":"10","author":"Docherty","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"joi240055r33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.122.062644","article-title":"Empagliflozin in Black versus White patients with heart failure: analysis of EMPEROR-Pooled.","volume":"147","author":"Verma","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"joi240055r34","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cardfail.2021.09.012","article-title":"The association between socioeconomic status, sex, race\/ethnicity and in-hospital mortality among patients hospitalized for heart failure.","volume":"28","author":"Averbuch","year":"2022","journal-title":"J Card Fail"},{"issue":"3","key":"joi240055r35","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016601","article-title":"Contemporary reevaluation of race and ethnicity with outcomes in heart failure.","volume":"10","author":"Savitz","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"joi240055r36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jchf.2018.02.002","article-title":"Health status disparities by sex, race\/ethnicity, and socioeconomic status in outpatients with heart failure.","volume":"6","author":"Khariton","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"4","key":"joi240055r37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jchf.2022.11.014","article-title":"Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum.","volume":"11","author":"Butt","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"5","key":"joi240055r38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jchf.2022.11.021","article-title":"Omecamtiv mecarbil in Black patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.","volume":"11","author":"Lanfear","year":"2023","journal-title":"JACC Heart Fail"},{"key":"joi240055r39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pcad.2022.04.010","article-title":"Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: an analysis of the GUIDE-IT study.","volume":"71","author":"Pahuja","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"joi240055r40","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00568-w","article-title":"\u201cAll of Us\u201d genetics chart stirs unease over controversial depiction of race.","author":"Kozlov","year":"2024","journal-title":"Nature"},{"issue":"4","key":"joi240055r41","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11121-022-01482-1","article-title":"Prevention science and health equity: a comprehensive framework for preventing health inequities and disparities associated with race, ethnicity, and social class.","volume":"24","author":"Biglan","year":"2023","journal-title":"Prev Sci"},{"key":"joi240055r42","doi-asserted-by":"crossref","DOI":"10.1007\/s40615-023-01872-3","article-title":"Race and ethnicity disparities in cardiovascular and cancer mortality: the role of socioeconomic status-a systematic review and meta-analysis.","author":"Mar\u00f4co","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"joi240055r43","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007917","article-title":"Race, racism, and cardiovascular health: applying a social determinants of health framework to racial\/ethnic disparities in cardiovascular disease.","volume":"15","author":"Javed","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"1","key":"joi240055r44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jacc.2010.03.043","article-title":"Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry\u2019s PINNACLE (Practice Innovation and Clinical Excellence) program.","volume":"56","author":"Chan","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"joi240055r45","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.jacc.2008.01.028","article-title":"Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry.","volume":"51","author":"Yancy","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"joi240055r19","unstructured":"Collection of race and ethnicity data in clinical trials and clinical studies for FDA-regulated medical products. US Food and Drug Administration. Posted January 2024. Accessed 12 March 2024, https:www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2819299\/jama_shen_2024_oi_240055_1718317238.8961.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:05:11Z","timestamp":1719313511000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2819299"}},"subtitle":["A Meta-Analysis of Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":45,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.6774","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,25]]}}}